References
This list gathers together the book's external evidence base: the peer-reviewed, citable literature behind the clinical claims. The main text of the book is written in patient-friendly language and does not replace these sources — here the interested reader (and the treating physician) will find the foundation.
References
[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link
Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.
[36] Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017. Link
European consensus conference developing evidence-based recommendations on FMT for clinical practice, with 28 experts from 10 countries collaborating in working groups. Statements were generated through evidence-based review, evaluated electronically via a Delphi process, and finalized in a plenary consensus session. Recommendations cover FMT indications, donor selection, faecal material preparation, clinical management, faecal delivery, and minimum requirements for establishing an FMT centre. Provides the European standardization framework for safe and governed FMT delivery.
[45] Kao D, Roach B, Silva M et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017. Link
Noninferiority randomized trial in 116 adults with recurrent CDI across three Canadian academic centres comparing oral capsule FMT with colonoscopy-delivered FMT (enrolment 2014–2016; noninferiority margin 15\%). The study tested whether less invasive capsule delivery matches colonoscopy in preventing further CDI recurrence. Results support clinical equivalence between routes, enabling broader and lower-burden access to FMT for recurrent CDI.
[59] Thaiss CA, Zeevi D, Levy M et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. 2014. Link
Mechanistic study in mice and humans demonstrating that the gut microbiota exhibits diurnal oscillations driven by feeding rhythms, producing time-specific compositional and functional profiles. Disruption of host molecular clock components or jet lag caused aberrant microbiota oscillations and dysbiosis through impaired feeding rhythmicity. Jet-lag-induced dysbiosis in both species promoted glucose intolerance and obesity that were transferable by FMT to germ-free recipients. Identifies microbiota–host circadian cross-regulation as a metabolic disease mechanism.
[159] Chassaing B, Koren O, Goodrich JK et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015. Link
In wild-type mice, relatively low concentrations of two ubiquitous emulsifiers — carboxymethylcellulose (CMC) and polysorbate-80 (P80) — induced low-grade inflammation and obesity/metabolic syndrome, and promoted robust colitis in mice predisposed to it. The mucus-protective barrier and microbiota composition were disrupted. The findings implicate dietary emulsifiers, ubiquitous components of processed foods, in the post-mid-20th-century rise in inflammatory bowel disease and metabolic disorders.
[160] Chassaing B, Van de Wiele T, De Bodt J, Marzorati M, Gewirtz AT. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017. Link
Using the M-SHIME ex vivo human microbiota model that excludes host inflammation as a confounder, both carboxymethylcellulose (CMC) and polysorbate 80 (P80) acted directly on the human microbiota to increase its pro-inflammatory potential, evidenced by elevated bioactive flagellin. The CMC-induced flagellin rise was rapid (1 day) and driven by altered microbial gene expression. The findings establish that these dietary emulsifiers exert direct, host-independent pro-inflammatory effects on the human gut microbiota.
[204] Allen JM, Mailing LJ, Niemiro GM et al. Exercise alters gut microbiota composition and function in lean and obese humans. Med Sci Sports Exerc. 2018. Link
This 6-week endurance training trial in 32 previously sedentary lean (n=18) and obese (n=14) adults assessed exercise-induced changes in gut microbiota composition, function and metabolite output, followed by a 6-week sedentary washout. Training progressed from 30 to 60 minutes at 60-75% of HR reserve, three days per week. Beta-diversity analysis showed that exercise-induced microbiota alterations were dependent on obesity status. The findings indicate that endurance training reshapes the gut microbiota in a host-phenotype-dependent manner, with effects partly reversible upon return to inactivity.
[207] Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015. Link
This review summarizes preclinical evidence that the gut microbiota influences the bidirectional CNS-ENS-GI axis. Germ-free rodent studies show that microbiota shape emotional behaviour, stress- and pain-modulation systems and brain neurotransmitters. Probiotic and antibiotic perturbations modulate these endpoints in adult animals. Multiple endocrine and neurocrine pathways mediate microbiota-to-brain signalling, while the brain alters microbial composition via the autonomic nervous system. Translation of these findings to healthy humans and gut-brain axis disorders remains limited and is identified as a research priority.
[218] Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. 2011. Link
This longitudinal study examined the distal gut microbiota of three individuals over 10 months spanning two courses of ciprofloxacin, analyzing 1.7 million 16S rRNA sequences from 52-56 samples per subject. Interindividual variation dominated; baseline within-subject communities were stable over months. Ciprofloxacin profoundly reduced diversity and shifted composition within 3-4 days of initiation, with incomplete and individual-specific recovery. The findings characterize gut microbiota resilience and the durable disruption caused by repeated fluoroquinolone exposure.
[339] Suez J, Zmora N, Zilberman-Schapira G et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018. Link
In a controlled study of post-antibiotic microbiome reconstitution, multi-strain probiotic supplementation, autologous fecal microbiota transplantation (aFMT) or spontaneous recovery were compared in mice and humans, sampled via invasive mucosal biopsies. Antibiotics enhanced probiotic mucosal colonization in humans but only mildly in mice. Compared with spontaneous recovery, probiotics induced a markedly delayed and persistently incomplete reconstitution of indigenous stool and mucosal microbiota and host transcriptome, while aFMT produced rapid, near-complete recovery within days. In vitro, Lactobacillus-secreted soluble factors contributed to probiotic-mediated suppression of indigenous taxa. The findings caution against routine post-antibiotic probiotic use and support aFMT as a recovery strategy.
[346] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015. Link
In an active 2011 population- and laboratory-based surveillance across ten US areas, 15,461 incident C. difficile infection cases were identified. 65.8% were health-care associated, but only 24.2% had hospital-onset disease, indicating that most health-care-associated cases were diagnosed after discharge or in non-acute settings. National estimates derived from regression modeling indicated approximately 453,000 incident CDI cases, 83,000 first recurrences and 29,300 deaths within 30 days of diagnosis annually. NAP1 strains predominated among health-care-associated isolates. The study established CDI as a leading cause of US healthcare-associated infection and a growing community burden.
[347] Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med. 2020. Link
Building on the Emerging Infections Program surveillance in ten US sites, the authors estimated the national burden of C. difficile infection from 2011 to 2017, adjusting for the higher sensitivity of NAAT-based diagnostics. The estimated total burden decreased over the period, driven largely by a reduction in health-care-associated CDI, while community-associated CDI remained stable. First-recurrence rates and in-hospital deaths also declined modestly. Trends were modeled with weighted random-intercept negative-binomial and logistic regression. The findings indicate that US-wide infection-prevention efforts have measurably reduced the health-care-associated CDI burden without comparable progress on community-associated disease.
[349] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021. Link
This 2021 IDSA/SHEA focused-update guideline addresses fidaxomicin and bezlotoxumab in adult C. difficile infection (CDI) management. Recommendations were derived from systematic literature review and graded using GRADE. The panel recommends fidaxomicin over vancomycin for initial CDI episode and for first recurrence (conditional, moderate certainty), citing reduced recurrence risk. Bezlotoxumab is suggested as adjunct to standard antibiotic therapy for patients at high risk of CDI recurrence (conditional, very low certainty). The update reflects accumulating RCT evidence and refines positioning of newer agents within the CDI treatment algorithm.
[357] Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997. Link
The authors evaluated the responsiveness of the Bristol Stool Form Scale to changes in whole-gut transit time (WGTT). Sixty-six volunteers had WGTT measured with radiopaque markers and recorded stool form on a 7-point scale and defecation frequency; measurements were repeated under senna and loperamide. Baseline WGTT correlated with frequency (r=0.35, P=0.005) and stool output (r=-0.41, P=0.001), and best with stool form (r=-0.54, P<0.001). Senna (n=44) shortened WGTT and increased frequency, form score and output (all P<0.001); loperamide (n=43) lengthened WGTT and reduced frequency, form score and output (all P<0.001). The Bristol scale is a valid surrogate for intestinal transit time and is responsive to pharmacological alteration.
[365] Reed AD, Theriot CM. Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium. Microorganisms. 2021. Link
This review examines how commensal Clostridium species mediate colonization resistance against C. difficile. Commensal Clostridia modify primary bile acids into secondary bile acids that suppress C. difficile spore germination and vegetative outgrowth. They additionally produce antimicrobial peptides and short-chain fatty acids that directly inhibit C. difficile and compete for limiting nutrients such as proline, important for C. difficile growth via Stickland fermentation. Loss of commensal Clostridia after broad-spectrum antibiotics is a key mechanistic step toward CDI susceptibility. The authors argue that restoring defined Clostridium consortia is a rational, mechanism-driven alternative to FMT for preventing recurrent CDI.
[369] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015. Link
This study tracked fecal microbiota dynamics in four patients with multiply recurrent, antibiotic-refractory C. difficile infection treated with FMT, sampling daily up to 28 days and weekly up to 84 days post-FMT (with sampling out to 151 days). 16S rRNA gene profiling was compared to Human Microbiome Project body-site references. Pre-FMT samples were markedly dysbiotic. FMT produced a rapid normalization of fecal community composition toward a healthy donor-like state within days, and this normalization was largely sustained over months. Time-course visualization highlighted both rapid early shifts and longer-term stabilization. The findings document the kinetics of FMT-driven microbiota recovery in refractory CDI and support its durability.
[637] Sonnenburg ED, Smits SA, Tikhonov M et al. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016. Link
The gut is home to trillions of microorganisms that have fundamental roles in many aspects of human biology, including immune function and metabolism. The reduced diversity of the gut microbiota in Western populations compared to that in populations living traditional lifestyles presents the question of which factors have driven microbiota change during modernization. Microbiota-accessible carbohydrates (MACs) found in dietary fibre have a crucial involvement in shaping this microbial ecosystem, and are notably reduced in the Western diet (high in fat and simple carbohydrates, low in fibre) compared with a more traditional diet. Here we show that changes in the microbiota of mice consuming a low-MAC diet and harbouring a human microbiota are largely reversible within a single generation. However, over several generations, a low-MAC diet results in a progressive loss of diversity, which is not recoverable after the reintroduction of dietary MACs. To restore the microbiota to its original state requires the administration of missing taxa in combination with dietary MAC consumption.
[2721] Palleja A, Mikkelsen KH, Forslund SK et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology. 2018. Link
Shotgun-metagenomic study of 12 healthy men: after a 4-day course of three last-resort antibiotics (meropenem, gentamicin, vancomycin) the gut microbiota largely but incompletely recovered over six months — several common species stayed missing and resistance genes were transiently enriched.
[2722] Grosen AK et al. Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort study. The Lancet Microbe. 2025. Link
Single-centre, prospective Danish cohort: clinical donor characteristics — including antibiotic exposure in the 12 months before donation and donation stool consistency — affect FMT success in recurrent C. difficile infection; donor antibiotic use worsens outcomes, supporting strict donor screening.
Note: the items above provide the book's external, citable evidence base. The internal, MicroBiome Bank source documents (DiffBiome / HospBiome Service Datasheet, SIS Clinical Guide, Clinical protocol guide v2.1, capsule density protocol, DSQ cards, C. diff clearance strategy 2026) supply the product- and protocol-specific facts; these are not public literature items but the provider's own, referenced documents.